{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:03:49Z","timestamp":1784538229020,"version":"3.55.0"},"reference-count":16,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Chronic total coronary occlusion (CTO) is frequently associated with persistent angina, functional limitation, and impaired health-related quality of life. Although CTO percutaneous coronary intervention (CTO-PCI) has improved technically, its clinical value is best assessed through patient-reported outcomes (PROs) and patient-centered clinical endpoints. This study evaluated the association between CTO-PCI plus optimal medical therapy (OMT) and 12-month patient-reported and clinical outcomes compared with OMT alone. Methods: This single-center, non-randomized retrospective observational cohort analysis included 251 patients with chronic coronary syndrome and angiographically confirmed CTO. Patients were managed with either a CTO-PCI + OMT strategy (n = 153) or OMT alone (n = 98). The analysis used routinely collected clinical, angiographic, echocardiographic, procedural, and follow-up data, complemented by patient-reported Seattle Angina Questionnaire (SAQ) data obtained after written informed consent. The overall SAQ assessment was considered the primary patient-reported framework, and SAQ Angina Frequency was defined as the principal symptom-specific domain for adjusted comparative analysis. Propensity-score overlap weighting was used as a sensitivity analysis to address measured baseline imbalance and treatment-selection bias. Secondary outcomes included Canadian Cardiovascular Society angina class, left ventricular ejection fraction, cumulative 12-month cardiovascular rehospitalization, and survival. Results: The complete-case SAQ population included 217 patients: 136 in the CTO-PCI + OMT group and 81 in the OMT group. Thirty-four patients lacked complete 12-month SAQ data: 24 died before SAQ reassessment, and 10 were lost to SAQ follow-up. SAQ Angina Frequency improved in both groups, from 70.81 \u00b1 17.97 to 92.35 \u00b1 12.37 in the CTO-PCI + OMT group and from 63.09 \u00b1 20.10 to 83.09 \u00b1 15.14 in the OMT group. In the multivariable ANCOVA model, CTO-PCI + OMT was associated with higher 12-month SAQ Angina Frequency compared with OMT alone (\u03b2 = 7.07 points; 95% CI, 3.36\u201310.79; p &lt; 0.001). This finding remained consistent in the propensity-score overlap-weighted sensitivity analysis adjusted for baseline SAQ Angina Frequency (\u03b2 = 6.55 points; 95% CI, 2.39\u201310.70; p = 0.002). Cardiovascular rehospitalization was observed in 11 of 153 patients (7.2%) in the CTO-PCI + OMT group and in 19 of 98 patients (19.4%) in the OMT group, corresponding to lower odds of cumulative 12-month rehospitalization (OR = 0.32; 95% CI, 0.15\u20130.71; p = 0.005). The rehospitalization endpoint was analyzed as a cumulative binary outcome rather than as a time-to-event outcome. Overall survival estimates were 92.0% and 87.4%, respectively, with 12 deaths in each group (log-rank p = 0.225). Because only 24 deaths were recorded, the study was underpowered to evaluate mortality differences. Conclusions: In selected patients with chronic coronary syndrome and CTO, CTO-PCI + OMT was associated with greater improvement in disease-specific health status, particularly SAQ Angina Frequency, compared with OMT alone. CTO-PCI + OMT was also associated with lower cumulative 12-month cardiovascular rehospitalization, although this secondary finding should be interpreted cautiously because of the non-randomized retrospective design, modest event numbers, lack of time-to-event rehospitalization data, and potential expectation- and care-related biases. Survival analyses were underpowered and should not be interpreted as evidence of either prognostic benefit or absence of benefit. These findings support consideration of CTO-PCI as a patient-centered therapeutic option in carefully selected symptomatic patients, while acknowledging residual confounding by indication and the open-label study design.<\/jats:p>","DOI":"10.3390\/jcm15145668","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:54:13Z","timestamp":1784534053000},"page":"5668","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Reported Health Status and Clinical Outcomes After CTO-PCI Versus Optimal Medical Therapy: A 12-Month Retrospective Observational Cohort Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0174-5084","authenticated-orcid":false,"given":"Velina","family":"Doktorova","sequence":"first","affiliation":[{"name":"First Department of Internal Diseases, Section of Cardiology, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria"},{"name":"Department of Interventional Cardiology, UMHAT \u201cSveti Georgi\u201d, 4000 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-8476","authenticated-orcid":false,"given":"Georgi","family":"Goranov","sequence":"additional","affiliation":[{"name":"First Department of Internal Diseases, Section of Cardiology, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria"},{"name":"Department of Interventional Cardiology, UMHAT \u201cSveti Georgi\u201d, 4000 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Nikolov","sequence":"additional","affiliation":[{"name":"First Department of Internal Diseases, Section of Cardiology, Medical University of Plovdiv, 4000 Plovdiv, Bulgaria"},{"name":"Department of Interventional Cardiology, UMHAT \u201cSveti Georgi\u201d, 4000 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariyan","family":"Marinov","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Section of Interventional Cardiology, MHAT \u201cSveti Ivan Rilski\u201d, 4000 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jacc.2011.12.007","article-title":"Current perspectives on coronary chronic total occlusions: The Canadian Multicenter Chronic Total Occlusions Registry","volume":"59","author":"Fefer","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Xenogiannis, I., Pavlidis, A.N., and Karamasis, G.V. (2024). Editorial: Contemporary percutaneous interventions for coronary chronic total occlusions. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1495936"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Synetos, A., Koliastasis, L., Ktenopoulos, N., Katsaros, O., Vlasopoulou, K., Drakopoulou, M., Apostolos, A., Tsalamandris, S., Latsios, G., and Toutouzas, K. (2025). Recent Advances in Coronary Chronic Total Occlusions. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051535"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/CIRCULATIONAHA.118.031313","article-title":"Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion","volume":"139","author":"Lee","year":"2019","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/eurheartj\/ehy220","article-title":"A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions","volume":"39","author":"Werner","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jcin.2018.04.017","article-title":"The IMPACTOR-CTO Trial","volume":"11","author":"Obedinskiy","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Macherey-Meyer, S., Salem, K., Heyne, S., Meertens, M.M., Finke, K., Mauri, V., Baldus, S., Adler, C., and Lee, S. (2024). Percutaneous Coronary Intervention versus Optimal Medical Therapy in Patients with Chronic Total Occlusion: A Meta-Analysis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13102919"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e035671","DOI":"10.1161\/JAHA.124.035671","article-title":"Long-Term Survival and Angina After Chronic Total Occlusion Percutaneous Coronary Intervention Compared with Medical Therapy: A Meta-Analysis","volume":"13","author":"Coerkamp","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Werner, G.S., Kim, J.-H., Hildick-Smith, D., Kang, D.-Y., Martin Yuste, V., Ahn, J.-M., Boudou, N., Park, D.-W., Louvard, Y., and Christiansen, E.H. (2026). Quality of Life After Percutaneous Coronary Intervention or Medical Therapy for Chronic Total Coronary Occlusions: EUROCTO and DECISION-CTO Meta-Analysis. J. Am. Coll. Cardiol., Online ahead of print.","DOI":"10.1016\/j.jacc.2026.02.5099"},{"key":"ref_11","unstructured":"Khan, S., Sajjad, U., Fawaz, S., Butt, H., Simpson, R., Ibrahim, A., Robertson, C., Kelly, P., Mohdnazri, S.R., and Tang, K. A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina: ORBITA-CTO. J. Am. Coll. Cardiol, Online ahead of print."},{"key":"ref_12","unstructured":"U.S. Food and Drug Administration (2009). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims: Guidance for Industry."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","article-title":"Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease","volume":"25","author":"Spertus","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa072771","article-title":"Effect of PCI on quality of life in patients with stable coronary disease","volume":"359","author":"Weintraub","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1916370","article-title":"Health-status outcomes with invasive or conservative care in coronary disease","volume":"382","author":"Spertus","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5668\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:14:38Z","timestamp":1784535278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":16,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145668"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145668","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}